Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy.
Level 2 - randomized trial
Post hoc analysis of an individual randomized controlled trial
PubMed 42156721 · doi:10.1038/s41467-026-72861-3
What was done
Researchers conducted a post hoc exploratory epigenetic age analysis of a 32-week, randomized, double-blind, placebo-controlled phase 2b trial (NCT04019197) of semaglutide in adults with HIV-associated lipohypertrophy. Peripheral-blood DNA methylation was profiled at baseline and week 32 to compare semaglutide (n = 45) versus placebo (n = 39) on first-, second-, and third-generation epigenetic aging clocks.
What was found
Adjusted analyses showed semaglutide reduced epigenetic aging across multiple measures compared to placebo: - PhenoAge: -4.9 years/year (p = 0.004) - PCGrimAge: -3.1 (p = 0.007) - GrimAge V2: -2.3 (p = 0.009) - OMICmAge: -2.2 (p = 0.009) - RetroAge: -2.2 (p = 0.030) - DunedinPACE: -0.09 units (9% slower, p = 0.01) Systems-based clocks also showed parallel reductions in inflammation, brain, and heart aging measures.
Why it matters
This provides initial clinical-trial evidence that GLP-1 receptor agonists can decelerate biological aging in humans, supporting their potential investigation as gerotherapeutics.
Limits
The epigenetic endpoint was not pre-specified and evaluated post hoc. The sample size was modest (n = 84 total), duration was limited to 32 weeks, and the population was restricted to adults with HIV-associated lipohypertrophy, limiting generalizability.
Cited by
- partial A preprint study led by Michael Corley found that semaglutide-induced weight loss in obese individuals over 33 weeks produced significant rejuvenation across all tested DNA methylation clocks.